Savara Inc (SVRA)

$5.72 +0.13 (2.33%)
Market Cap 1.14B
Revenue (ttm) 0.00
Net Income (ttm) -95.88M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 1,367,300
Avg Vol 2,260,628
Day's Range N/A - N/A
Shares Out 203.47M
Stochastic %K 51%
Beta 0.34
Analysts Strong Sell
Price Target $10.81

Company Profile

Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company was founded in 2007 and is headquartered in Langhorne, Pennsylvania.

Industry: Biotechnology
Sector: Healthcare
Phone: 512 614 1848
Address:
1717 Langhorne Newtown Road, Suite 300, Langhorne, United States
Richterscale
Richterscale Feb. 19 at 8:23 PM
$SVRA Paul’s said news by end of month on BLA. Also Oppenheimer conference next week. News right before conference?
1 · Reply
ckruel
ckruel Feb. 19 at 6:51 PM
$SVRA https://tipranks.onelink.me/WJho/x8rbplgn Savara provides update
0 · Reply
NeverFadeTheOracle
NeverFadeTheOracle Feb. 19 at 5:39 AM
$SVRA Good spec biotech here Pulmonary, one of my favorite sectors
0 · Reply
Richterscale
Richterscale Feb. 17 at 2:00 AM
$SVRA If approved guesses on the SP$?? Does that put us back in the $8-11 range?
2 · Reply
Richterscale
Richterscale Feb. 17 at 1:59 AM
$SVRA https://www.marketbeat.com/instant-alerts/savara-eyes-august-pdufa-for-molbreevi-as-fda-bla-filing-decision-nears-execs-say-at-summit-2026-02-15/
0 · Reply
Richterscale
Richterscale Feb. 16 at 1:47 AM
$SVRA I know I post a lot but I’ve been trading this for 10+ years. I’m actually positive when I’m not normally on Bio stocks . Shares for employees ( encumbet)..the board got their shares.. Blackrock bought more ..ect. I’m positive on the next step. Although nothing is guaranteed
0 · Reply
Richterscale
Richterscale Feb. 12 at 9:36 PM
$SVRA News this month 11 business days. Good luck to all.
1 · Reply
topstockalerts
topstockalerts Feb. 12 at 6:21 PM
$SVRA Here comes the breakout as volume expands 📈. Buyers are chasing strength. That usually fuels continuation.
0 · Reply
ckruel
ckruel Feb. 12 at 5:52 PM
$SVRA that’s a nice pop today
0 · Reply
Zeffanator2
Zeffanator2 Feb. 12 at 5:31 PM
$SVRA Let’s see another 10%.
0 · Reply
Latest News on SVRA
Savara Announces New Employment Inducement Grant

Feb 13, 2026, 4:05 PM EST - 6 days ago

Savara Announces New Employment Inducement Grant

Savara Announces Participation in Upcoming Investor Healthcare Conferences

Feb 4, 2026, 4:05 PM EST - 15 days ago

Savara Announces Participation in Upcoming Investor Healthcare Conferences

Savara Announces Amendment to Hercules Capital Debt Facility Providing up to $75M of Additional Debt Funding Upon U.S. Food and Drug Administration (FDA) Approval of MOLBREEVI*

Jan 27, 2026, 8:05 AM EST - 24 days ago

Savara Announces Amendment to Hercules Capital Debt Facility Providing up to $75M of Additional Debt Funding Upon U.S. Food and Drug Administration (FDA) Approval of MOLBREEVI*

HTGC

Savara Inc. (SVRA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 15, 2026, 5:16 AM EST - 5 weeks ago

Savara Inc. (SVRA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

PANTHERx® Rare Selected by Savara as the U.S. Exclusive Specialty Pharmacy for MOLBREEVI*

Jan 8, 2026, 4:05 PM EST - 6 weeks ago

PANTHERx® Rare Selected by Savara as the U.S. Exclusive Specialty Pharmacy for MOLBREEVI*

Savara Resubmits the Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for MOLBREEVI* for the Potential Treatment of Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)

Dec 22, 2025, 8:30 AM EST - 2 months ago

Savara Resubmits the Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for MOLBREEVI* for the Potential Treatment of Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)

Savara Announces Participation in the 44th Annual J.P. Morgan Healthcare Conference

Dec 17, 2025, 8:05 AM EST - 2 months ago

Savara Announces Participation in the 44th Annual J.P. Morgan Healthcare Conference

Savara Announces European Patent Office (EPO) Intends to Grant a Patent for the Liquid Formulation of MOLBREEVI*

Dec 11, 2025, 8:05 AM EST - 2 months ago

Savara Announces European Patent Office (EPO) Intends to Grant a Patent for the Liquid Formulation of MOLBREEVI*

Savara and PARI Granted a European Patent Covering the Drug-Device Combination of MOLBREEVI* Delivered Via the Proprietary eFlow® Nebulizer System

Dec 2, 2025, 8:05 AM EST - 2 months ago

Savara and PARI Granted a European Patent Covering the Drug-Device Combination of MOLBREEVI* Delivered Via the Proprietary eFlow® Nebulizer System

Savara: A High-Risk Opportunity

Nov 16, 2025, 6:35 AM EST - 3 months ago

Savara: A High-Risk Opportunity

Savara Reports Third Quarter 2025 Financial Results and Provides Business Update

Nov 12, 2025, 4:05 PM EST - 3 months ago

Savara Reports Third Quarter 2025 Financial Results and Provides Business Update

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of November 7, 2025 in Savara Inc. Lawsuit – SVRA

Nov 5, 2025, 5:54 PM EST - 3 months ago

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of November 7, 2025 in Savara Inc. Lawsuit – SVRA

Savara Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Total Gross Proceeds of $149.5M

Oct 31, 2025, 4:05 PM EDT - 3 months ago

Savara Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Total Gross Proceeds of $149.5M

SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Savara

Oct 30, 2025, 11:05 AM EDT - 4 months ago

SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Savara

Savara Announces Pricing of $130.0 Million Public Offering of Common Stock and Pre-funded Warrants

Oct 29, 2025, 9:43 PM EDT - 4 months ago

Savara Announces Pricing of $130.0 Million Public Offering of Common Stock and Pre-funded Warrants

Savara Announces Proposed Public Offering

Oct 29, 2025, 4:07 PM EDT - 4 months ago

Savara Announces Proposed Public Offering

Savara announces $75M Royalty Funding Agreement with RTW to Support the Potential Launch of MOLBREEVI* in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)

Oct 29, 2025, 4:01 PM EDT - 4 months ago

Savara announces $75M Royalty Funding Agreement with RTW to Support the Potential Launch of MOLBREEVI* in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Savara

Oct 28, 2025, 9:58 AM EDT - 4 months ago

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Savara

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Savara

Oct 23, 2025, 1:36 PM EDT - 4 months ago

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Savara

Savara Announces Chief Medical Officer (CMO) Transition

Oct 17, 2025, 8:05 AM EDT - 4 months ago

Savara Announces Chief Medical Officer (CMO) Transition

SAVARA DEADLINE REMINDER: Bragar Eagel & Squire, P.C. Reminds Savara Investors to Contact the Firm Before the November 7th Deadline

Oct 14, 2025, 12:14 PM EDT - 4 months ago

SAVARA DEADLINE REMINDER: Bragar Eagel & Squire, P.C. Reminds Savara Investors to Contact the Firm Before the November 7th Deadline

SVRA INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Savara

Oct 12, 2025, 8:44 AM EDT - 4 months ago

SVRA INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Savara

Savara: Back On Track With Upcoming APAP BLA Filing

Oct 9, 2025, 7:42 AM EDT - 4 months ago

Savara: Back On Track With Upcoming APAP BLA Filing

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of November 7, 2025 in Savara Inc. Lawsuit - SVRA

Oct 6, 2025, 8:45 AM EDT - 4 months ago

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of November 7, 2025 in Savara Inc. Lawsuit - SVRA

Savara Announces Encore Presentations of Results From the Phase 3 IMPALA-2 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at CHEST 2025

Oct 2, 2025, 4:05 PM EDT - 5 months ago

Savara Announces Encore Presentations of Results From the Phase 3 IMPALA-2 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at CHEST 2025

Savara Presents New Data From the Phase 3 IMPALA-2 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the European Respiratory Society (ERS) Congress 2025

Sep 29, 2025, 2:00 AM EDT - 5 months ago

Savara Presents New Data From the Phase 3 IMPALA-2 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the European Respiratory Society (ERS) Congress 2025

Savara Announces New U.S. Health Claims Data Analysis Finds Over 50% Increase in the Estimated Number of Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) Patients Compared to Previous Claims Analysis

Sep 2, 2025, 9:00 AM EDT - 6 months ago

Savara Announces New U.S. Health Claims Data Analysis Finds Over 50% Increase in the Estimated Number of Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) Patients Compared to Previous Claims Analysis

New England Journal of Medicine (NEJM) to Publish Results From Savara's Pivotal Phase 3 IMPALA-2 Clinical Trial in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)

Aug 20, 2025, 5:15 PM EDT - 6 months ago

New England Journal of Medicine (NEJM) to Publish Results From Savara's Pivotal Phase 3 IMPALA-2 Clinical Trial in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)

Savara to Present New Data from the Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the European Respiratory Society Congress 2025

Aug 18, 2025, 8:05 AM EDT - 6 months ago

Savara to Present New Data from the Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the European Respiratory Society Congress 2025

Savara Reports Second Quarter 2025 Financial Results and Provides a Business Update

Aug 13, 2025, 8:05 AM EDT - 6 months ago

Savara Reports Second Quarter 2025 Financial Results and Provides a Business Update

Richterscale
Richterscale Feb. 19 at 8:23 PM
$SVRA Paul’s said news by end of month on BLA. Also Oppenheimer conference next week. News right before conference?
1 · Reply
ckruel
ckruel Feb. 19 at 6:51 PM
$SVRA https://tipranks.onelink.me/WJho/x8rbplgn Savara provides update
0 · Reply
NeverFadeTheOracle
NeverFadeTheOracle Feb. 19 at 5:39 AM
$SVRA Good spec biotech here Pulmonary, one of my favorite sectors
0 · Reply
Richterscale
Richterscale Feb. 17 at 2:00 AM
$SVRA If approved guesses on the SP$?? Does that put us back in the $8-11 range?
2 · Reply
Richterscale
Richterscale Feb. 17 at 1:59 AM
$SVRA https://www.marketbeat.com/instant-alerts/savara-eyes-august-pdufa-for-molbreevi-as-fda-bla-filing-decision-nears-execs-say-at-summit-2026-02-15/
0 · Reply
Richterscale
Richterscale Feb. 16 at 1:47 AM
$SVRA I know I post a lot but I’ve been trading this for 10+ years. I’m actually positive when I’m not normally on Bio stocks . Shares for employees ( encumbet)..the board got their shares.. Blackrock bought more ..ect. I’m positive on the next step. Although nothing is guaranteed
0 · Reply
Richterscale
Richterscale Feb. 12 at 9:36 PM
$SVRA News this month 11 business days. Good luck to all.
1 · Reply
topstockalerts
topstockalerts Feb. 12 at 6:21 PM
$SVRA Here comes the breakout as volume expands 📈. Buyers are chasing strength. That usually fuels continuation.
0 · Reply
ckruel
ckruel Feb. 12 at 5:52 PM
$SVRA that’s a nice pop today
0 · Reply
Zeffanator2
Zeffanator2 Feb. 12 at 5:31 PM
$SVRA Let’s see another 10%.
0 · Reply
topstockalerts
topstockalerts Feb. 12 at 4:53 PM
$SVRA Interesting spot for a momentum swing 💡. Price is holding strength. Buyers are clearly engaged.
0 · Reply
Richterscale
Richterscale Feb. 12 at 1:09 AM
$SVRA is the AH real?
0 · Reply
Spacemonkey1
Spacemonkey1 Feb. 11 at 6:05 PM
$SVRA problem is in identifying patients, most likely, up until now, they’ve only identified real severe cases. Even amongst severe cases there appears to be a broad spectrum of severity, suggesting there may be a much larger population with mild to moderate symptoms. Antibody test certainly helps.
0 · Reply
Spacemonkey1
Spacemonkey1 Feb. 11 at 6:03 PM
$SVRA this could be a cash cow
0 · Reply
Spacemonkey1
Spacemonkey1 Feb. 11 at 6:01 PM
$SVRA listened to the chat, seems to be going well, I’m happy about the optimism in identifying new patients and the success of their pilot program at UF
0 · Reply
Richterscale
Richterscale Feb. 11 at 6:00 PM
$SVRA Guggenheim conference any thoughts?
0 · Reply
Richterscale
Richterscale Feb. 10 at 9:00 PM
$SVRA What the fuck. In the first 2 minutes of opened it went red/green over a dozen times each increment getting bigger then up $.19 now just .03. Crazy manipulation
0 · Reply
ckruel
ckruel Feb. 9 at 9:05 PM
$SVRA Savara Insiders Added US$535.6k Of Stock To Their Holdings
1 · Reply
Spacemonkey1
Spacemonkey1 Feb. 9 at 5:51 PM
$SVRA I think we’ve got some gamblers pushing the price down right now, betting on FDA being slow
1 · Reply
Richterscale
Richterscale Feb. 9 at 5:19 PM
$SVRA https://www.marketbeat.com/instant-alerts/savara-inc-nasdaqsvra-given-consensus-recommendation-of-moderate-buy-by-analysts-2026-02-05/
0 · Reply
UgoGreg
UgoGreg Feb. 8 at 2:52 PM
$SVRA https://youtu.be/b4CDDEB3OQo
0 · Reply
biovaluable
biovaluable Feb. 5 at 3:17 PM
$SVRA good
1 · Reply